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1. Introduction 
Despite the novel pathogenetic and therapeutic acquisitions sepsis remains the main cause 
of death in the critically ill patient (p.). The incidence of sepsis is increasing, with more than 
750 000 cases occurring in the United States every year; sepsis is complicated by organ 
dysfunction giving rise to severe sepsis which causes more than 200 000 deaths each year 
[1]. The cardiovascular syndrome is the cause of the major part of the fatalities leading to 
the picture of the septic shock with 90,000 deaths annually. The myocardial dysfunction in 
sepsis has been widely studied and many causes of heart dysfunction have been described. 
The presence of a metabolic compromise is well known in chronic heart failure and has been 
considered as a basis for contractile failure, interestingly similar alterations have been 
recently described also in sepsis. The purpose of this study is to examine the current 
available data on this topic. 
Sepsis has been defined as the systemic host reaction to an infection [2]. The typical immune 
response in sepsis presents a first stage, characterized by an increased production of 
proinflammatory interleukins (ILs) by monocytes, macrophages. lymphocytes and endothelial 
cells in response to a few molecules, common to all virulent pathogens, called pathogen-
associated molecular patterns (PAMPs) [3]. They are recognized by receptors on the surface of 
the immune cells, named Pattern Recognition Receptors (PRP) the most important being the 
Toll-like Receptors (TLRs), existing in 13 different types each recognizing a different microbial 
constituent. TLR are an important component of immune activity programmed to respond 
quickly to the infectious challenges by recognizing PAMP. Lipopolysaccharide (LPS) in 
particular is recognized by the complex TLR4-CD14 in the plasma membrane and the 
inflammatory signal is transduced by the recruitment of the adaptor molecules that associate 
with the intracellular Toll/interleukin-1 receptor (TIR) domain of the TLR to initiate signal 
transduction. Of these adaptor molecules myeloid differentiation primary- response protein 88 
(MyD88) is associated with all TLRs except TLR3 while the TIR-domain containing adaptor 
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inducing interferon (IFN)-β (TRIF) is only associated to TLR3 [3]. Both of them lead to nuclear 
factor-κB (NF-kB) activation and induction of over 150 inflammatory and procoagulant genes 
with increased expression of the proinflammatory ILs tumor necrosis factor TNF), IL1, 
IL6, interferon  (IFN), chemokines and cell adhesion molecules. This phase, named Systemic 
Inflammatory Reaction Syndrome (SIRS) is followed by a second phase, the compensatory 
anti- inflammatory response syndrome (CARS), that modulates SIRS through death by 
apoptosis of immune cells, gene silencing of the pro-inflammatory genes and increased 
production of the contra-inflammatory ILs IL10, IL4 and TGF[4-6] Through this biphasic 
reaction in the largest part of the cases the homeostasis is re-established. It is possible however 
that during the proinflammatory phase because of the “cytokine storm”-induced organ 
damage, further increased through the release by the injured tissue of the endogenous 
damage-associated molecular pattern (DAMPs or alarmins such as hig mobility group protein 
B1(HMBG1), hyaluronan, HSP, proteins S100 etc), as more frequently occurs in young and 
reactive people, or during the contra-inflammatory phase, due to immunosuppression and 
diffuse infection, death may ensue [4]. The normal biphasic reaction may be altered when 
sepsis is present in very old and diseased persons that frequently present a mild phase of SIRS 
or do not present it at all; in the later stages it seems that immunosuppression is almost always 
present [7]. Indeed from what has been described it seems that in both the cases sepsis is 
characterized by an “altered immune response”, unbalanced [8] with prevalence of an 
excessive proinflammatory reaction in the early phase and a prevalent immunosuppression in 
the late phase [8.] The definition of sepsis based on the recent achievement on this topic could 
be reconsidered focusing more on the immune status, we propose the sequent definition: “ 
sepsis is the altered immune response to an infectious challenge, either increased or decreased, 
and followed by a compromised organ function”. The passage from the SIRS to the CARS is 
marked by the phenomenon of LPS tolerance [9]: the prolonged stimulation of TLR4, the 
specific receptor for endotoxin, by LPS leads to the silencing of proinflammatory genes and to 
the stimulation of the contra-inflammatory ones through a process of gene reprogramming 
[10] with increased expression of IL-10, TGF-β, and type I IFNs. Neutrophil function is 
seriously impaired in sepsis with the development of a decreased ability to migrate into the 
infection site, related to the severity of the disease [for review see 11]. During this stage 
macrophages exhibit an increased phagocytic ability but an altered capacity of antigen 
presentation due to reduced expression of several major histocompatibility complex (MHC) 
Class II molecules (e.g. HLA-DRs) with impaired T-cell proliferation as well as reduced 
production of IFN. This phase corresponds also to a stage of ischemic tolerance caused by the 
reduced production of NF-kB responsible for the amplification of the damage induced by 
ischemia [12]. TLRs are indeed involved in the tissue damage caused by non-infectious 
challenges such as ischemia-reperfusion injury (IRI), burns, surgery, trauma etc. because they 
mediate the inflammatory reaction to the alarmins released by these noxae: the deletion of 
TLR2 and TLR4 may reduce the cellular damage in these settings [13-14].The mitochondrial 
DNA released after tissue damage may be recognized by TLRs, behaving as a DAMP for its far 
origin by bacteria according to endosymbiotic theory; its experimental infusion may cause a 
picture similar to the ARDS [15]. TLRs are also important to explain the link between 
inflammation and metabolic alterations [16] and the state of low grade inflammation present 
for so far unknown reasons in obesity, metabolic syndrome, diabetes and in chronic 
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myocardial ischemia; moreover they may also be involved in the adipose tissue dysfunction 
described during sepsis [17,18]. One of the main problems in the study of sepsis has been its 
experimental reproduction: the LPS infusion method, used also at low doses in human 
volunteers, is not reliable because it reproduces only the proinflammatory phase and led in the 
past to misunderstand the complex regulation of immunity in sepsis, moreover in this model 
is lacking an infectious focus. The availability of successive different models such as the 
infusion of living bacteria and the cecal ligation and puncture (CLP), at present considered a 
good reproduction of human septic peritonitis, allowed further progress supplying models 
similar to human sepsis [19].  
2. Metabolic response in sepsis and injury 
The first phase of sepsis, coincident with SIRS and also called flow phase, is characterized by a 
state of hypercatabolism with negative nitrogen balance induced by the increase in 
proinflammatory ILs and stress hormones, while the anabolic ones are reduced. This phase is 
also marked by hyperglycemia, hyperlactatemia and increased energy expenditure varying 
with the nature of the injurious stress (15-20% after surgery, 20-40% in sepsis and up to 120% 
in burns [20]). Injury in general and sepsis in particular are associated with an increased 
protein breakdown (mainly derived by the muscle representing the main store of proteins in 
the body, up to 40% of total body proteins), protein catabolism in sepsis may reach 260 gr\day 
[21] corresponding to a loss of 1 Kg muscle, with negative nitrogen balance, an increased blood 
pool of amino acids (a.a.), used in the liver for neoglucogenesis and the production of acute 
phase proteins, and reduced uptake of a.a. by the muscle. The protein utilization as a fuel is 
opposite to the normal and rapidly depletes body lean mass. The increased production of IL-
1, IL-6 and TNFcauses protein catabolism both directly and indirectly through the 
stimulation of the HypothalamusPituitary-Adrenal (HPA) axis. The increased protein 
catabolism may be reproduced by counter-regulatory hormones infusion.  
2.1. Glucose metabolism and insulin sensitivity in sepsis  
Insulin resistance may be defined as the inability of insulin to adequately stimulate glucose 
uptake in the muscle or to inhibit gluconeogenesis in the liver [23]. The pathogenesis of the 
insulin resistance is no more interpreted on the basis of the glucocentric but of the lipocentric 
theory [24] stating that the excess of circulating free fatty acids (FFA), the main competitive 
inhibitors of glucose utilization in the cell, when present in excess in plasma because of 
increased lipolysis, decreased fat storing capacity of adipose tissue or reduced fatty acid 
oxydation (FAO) may accumulate in the organs (liver, myocardium, pancreas etc) giving 
origin to reduced sensitivity to insulin, increased hepatic glucose output and to the 
phenomenon of lipotoxicity, syndrome characterized by accumulation of FFA in the cell, 
increased production of reactive oxygen species (ROS), activation of apoptosis (lipoapoptosis) 
and organ dysfunction [25]. The etiology of insulin resistance in sepsis is related to the increase 
of the contra-insular substances (glucagon, TNF, growth hormone, cortisol) and to the 
reduced expression of the insulin-sensitizing adiponectin while the endogenous insulin 
secretion in the critically ill p. is increased as occurs in the early phase of type II diabetes 
mellitus, on the contrary of what was suggested in the past [26]. The consequences of the 
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metabolic storm in sepsis are an increased hepatic production of glucose, a reduced glucose 
uptake by insulin-dependent tissues, increased levels of FFA- consequence of the increased 
lipolysis- reduced FAO and reduced insulin sensitivity at the muscular and hepatic level [27]. 
The high levels of blood glucose allow a high uptake by the non-insulin-dependent cells 
because of the increased expression of the stress- and Ils-dependent glucose transporter 
GLUT1 [27]. In this way a high rate of glucose oxidation through mitochondria is made 
possible leading to an enhanced production of ROS: the increased oxidative and nitrosative 
stress, chiefly in presence of a reduction in ROS scavengers, -mainly glutathione[28]- typical of 
the critical states, may damage mainly the Complexes I and III of the electron transport chain 
(ETC) initiating the mitochondrial dysfunction. Insulin is provided with an anti-inflammatory 
action that is missing if a reduced sensitivity to its action is present, such as in critical illness, 
further increasing inflammation [27]. Proinflammatory ILs interfere with insulin activity 
through multiple mechanisms ; 1) TNF and other cytokines activate Jun-N-terminal kinase 
(JNK) responsible for serine phosphorylation of the insulin receptor substrate 1 (IRS-1) at Ser 
307, so disrupting insulin signalling [29] 2) furthermore JNK activation has been showed, in 
LPS-induced experimental sepsis, to depress PPAR expression reducing FFA oxidation [30]; 
JNK inhibition prevented cardiac dysfunction, despite continued induction of inflammatory 
markers, demonstrating that there is a dysmetabolic basis for LPS-induced cardiac dysfunction 
in this experimental setting [30]. An important clinical application of the role played by the 
altered glucose metabolism in the critically ill p. derived from the Leuven Study [31] that 
showed a striking reduction from 8% to 4,6% in the mortality of critically ill surgical p. 
receiving mechanical ventilation by maintaining glycemia between 80 and 110 mg% with 
intensive insulin therapy. However in 2009 the NICE SUGAR Study showed that a blood 
glucose target of 180 mg% or less per deciliter resulted in lower mortality than did a target of 
81 to 108 mg range, probably by reducing the incidence of hypoglycaemia [32]. A diffuse 
coverage of this matter is beyond the scope of this report (for review see reference [33]). 
Hyperlactatemia in sepsis has been considered as a consequence of the establishment of an 
hypoxic environment, this concept is however no longer tenable, except for the p. in septic 
shock, because in many organs an increased oxygen saturation has been showed both in 
clinical sepsis and after LPS infusion [34]. Currently the cause of hyperlactatemia is 
considered to be the increased expression of Hypoxia-inducible factor1 (HIF-1)- and of 
cytokines activating PDHK4, an enzyme inhibiting PDH (pyruvate dehydrogenase) through 
phosphorylation so preventing the transformation of pyruvate into acetyl-CoA and its 
oxidation through the TCA (Tricarboxilic acid Cycle); the excess of pyruvate is transformed 
into lactate by Lactate dehydrogenase (LDH) through a process called accelerated aerobic 
glycolysis [35-38]. The plasma levels of lactate seems to be related to the outcome [35]. 
2.2. TG and FFA utilization in the normal heart 
In a physiological environment rich in oxygen but also in pathophysiological conditions 
(like diet rich in lipids, starvation or diabetes) the heart can utilize all metabolites but it 
prefers FFA oxidation, from which it gets 60-90% of the necessary energy, obtaining the 
remaining part from the oxidation of glucose and ketone bodies [39]. The myocardiocyte 
gets FFA mainly taking up tryglicerides (TG)-rich lipoproteins (LP) (chylomicrons and very 
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low-density lipoprotein, VLDL) through the endothelial lipoprotein lipase (LPL), enzyme 
present in the capillary endothelium and bound to it through a proteoglycan, the 
Glycosylphosphatidyl-inositol high density lipoprotein-binding protein 1 (GPIHBP1), which 
anchors LPL to endothelium and serves as a bridge allowing LP uptake[40]. The myocardial 
cells may take up FFA also from the albumin-bound pool (10 time less abundant). FFA 
obtained from hydrolysis of TG by LPL or transported by albumin are then taken up by the 
myocardiocyte, through transporters, mainly FAT\CD36 (50-60%) but also by fatty acid 
binding protein (FABP) and fatty acid transport plasma membrane (FATPpm), only a very 
small part is taken up by diffusion [41]. Once transported into the cytosol, FFAs are 
esterified to long chain acyl CoA by fatty acyl CoA synthase (FACS) and transported for 
FFA oxidation(FAO) across mitochondrial membrane. This process is carried out in three 
steps: at first acyl-CoA is metabolized into acyl-carnitine by the enzyme carnitine palmitoyl 
transferase-1 (CPT-1), located on the outer mitochondrial membrane. Acyl-carnitine is hence 
transported across the inner mitochondrial membrane by carnitine translocase (CAT) and 
again transformed into long chain Acyl-CoA and carnitine by CPT- 2 (carnitine shuttle) [42]. 
The step catalyzed by CPT-1 is the rate-limiting reaction of FAO and the activity of this 
enzyme is strictly regulated by malonyl-CoA (the product of carboxylation of acetyl-CoA), 
whose levels are controlled by a balance between the activity of the enzymes involved in its 
metabolism, the acetyl CoA carboxylase (ACC) and malonyl CoA decarboxylase. AMP-
activated protein kinase (AMPK), a fundamental energy sensor in the cell, controls this 
reaction phosphorylating and inhibiting ACC whenever it senses a decrease in the 
ATP\AMP ratio [42]. In the normal heart, 75% of the fatty acids taken up are immediately 
oxidized. Acetyl-CoA has a central role in the regulation of the utilization of the substrates: 
it is the metabolic product of both glucose (through pyruvate) and fatty acid utilization. It 
may be utilized for oxidation in the Krebs cycle or, if the cellular level of ATP is high, used 
for FFA synthesis. Acetyl-CoA may also be transformed into pyruvate and lactate by LDH 
in the presence of hypoxia but also when it is produced in huge quantities. More than 40 
years ago Randle described the reciprocal inhibition exercised by glucose and FFA 
utilization [43]. He displayed in the isolated heart and in a skeletal muscle preparation that 
the oxidation of one substrate inhibited directly, without hormonal intermediation, the use 
of the other (Randle cycle). So an increase in FAO causes a proportional decrease in glucose 
oxidation and uptake leading to hyperglycemia. The actual interpretation of Randle cycle is 
that an increase in serum concentration and uptake of FFA activates FAO and causes 
accumulation of its byproducts as ROS, ceramides, diacylglycerol, acyl-carnitine and fatty 
acyl-CoAs inside the skeletal muscle so depressing glucose uptake, whereas in the liver they 
inhibit insulin-mediated suppression of glycogenolysis and gluconeogenesis [44-45]. Also 
the increased lipolysis present in many conditions (fasting, exercise, inflammatory 
conditions, diabetes and obesity) leading to an increased FAO may downregulate glucose 
utilization through increased serum FFA and reduced insulin sensitivity. All these signals, 
particularly diacylglycerol, interfere with insulin signalling activating PKC novel isoforms 
() causing a reduced tyrosine phosphorylation of the IRS-1 which is normally 
responsible for the activation through phosphatidyl inositol 3-kinase (PI3K) and Akt of the 
membrane translocation of the insulin-dependent glucose transporter 4 (GLUT4)[46]. So an 
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increase in FAO causes a proportional decrease in glucose uptake and oxidation with 
hyperglycemia. This mechanism has been considered important in the pathophysiology of 
diabetes mellitus type2 (T2DM). Conversely glucose uptake and oxidation to acetyl CoA 
and pyruvate involves the conversion to malonylCoA by ACC leading to inhibition of CPT-
1 and consequently of FAO; moreover insulin decreases lipolysis and the level of FFA. 
During starvation increased lipolysis raises FFA uptake and oxidation inhibiting glucose 
oxidation and favouring accumulation of pyruvate and lactate redirected to glycogen 
synthesis allowing also glucose sparing for the brain. Conversely after a glucose rich meal 
the increased uptake and utilization of glucose inhibit the utilization of FFA through the 
accumulation of malonylCoA. The normal heart responds to an increase in workload by 
switching from FFA to preferential glucose utilization. The Randle cycle explains how the 
heart regulates the fuel selection in the short term to face physiologic challenges however 
the long-term adaptation to physiologic and pathophysiologic conditions is mediated by 
translational and post-translational modifications rather than by the metabolic ones. A 
fitting example is the metabolic switch occurring after birth. During the fetal life the heart, 
probably because of the relatively hypoxic medium, relies more on carbohydrate 
metabolism, whereas in the adult myocardiocyte glycogen occupies less than 2% of the cell 
volume, in the fetal cells it represents more than 30% of the cell volume [47]. After birth the 
heart, due probably to the increased availability of oxygen, prefers FFA oxidation because of 
the discontinuous availability of metabolites and the elevated fat content of mother’s milk; 
the metabolic shift is accompanied by increased expression of the enzymes involved in FAO. 
The utilization of both lipid and carbohydrates has advantages and drawbacks: the complete 
oxidation of a molecule of palmitic acid (molecular mass 256,43) yields more ATP (105 
molecules vs 31) but consumes much more oxygen (46 atoms vs 12) than the oxidation of a 
molecule of glucose. Moreover the oxidation of lipid produces more oxidative stress, a 
drawback partially corrected by the increased production of the uncoupling protein 
3(UCP3) and differently from anaerobic glycolysis it is not available in hypoxic or ischemic 
settings. Such long term substrate modifications are transcriptionally regulated and the 
switch to carbohydrate utilization is due to a downregulation of the nuclear receptors 
PPAR involved in the transcription of the enzymes of FFA transport and utilization. 
The key enzyme in the regulation of pyruvate metabolism is the PDH. The activity of cardiac 
PDH is mainly modulated by the PDH kinase (PDHK4), an isoform of the kinase 
phosphorylating and transforming PDH from the active to the inactive form. Short-term 
metabolic inhibition of PDHK4 is affected by pyruvate while its activation is affected by acetyl 
CoA and NADH. The long-term regulation is determined by many conditions characterized 
by insulin deficiency (diabetes) or resistance (starvation, high-fat diet, and hyperthyroidism) 
that increase PDHK expression, while insulin suppresses its production [35,36,38]. 
3. The metabolic myocardial switch 
In pathological conditions a long term modification in substrate preference may be present: the 
diabetic heart relies almost exclusively on FAO [48], on the contrary the myocardium submitted 
to mechanical, ischemic\hypoxic or inflammatory stress switches to the anaerobic glycolysis, 
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which can also continue in an environment poor in oxygen. Even though glycolysis allows a 
much lesser production of energy (2 molecules of ATP instead of 36 per molecule of glucose 
oxidized) through the transformation of pyruvate into lactate by LDH it presents the advantage 
to go on also in a hypoxic setting; however this process, which in the short-term is adaptive, in 
the long-term becomes maladaptive because of the reduced energy production [49]. The better 
the heart defends itself in the presence of stressful events, the more easily it is able to switch to 
the type of metabolism more efficient in that situation and the more it is provided with 
metabolic flexibility. Thus the survival of the myocardium depends, in these conditions, on an 
increased supply of glucose that is assured by the augmentation of the main transmembrane 
glucose transporters, GLUT1 and GLUT4. GLUT1 is present ubiquitously, augments in 
presence of reduced glucose levels and during inflammatory, metabolic and osmotic stress [50]; 
GLUT4 is present in the adipose tissue, heart, liver and in the striated muscle and is the typical 
insulin-dependent transporter. The increase in glucose transporters, mainly in GLUT1, has an 
adaptive meaning in the stressed heart; its overexpression protects against experimental 
ventricular hypertrophy, at least until cardiac failure appears, causing its downregulation [51]. 
This metabolic remodelling seems to be controlled by the fetal gene program, so called 
because it is present in the fetal environment, relatively hypoxic, and is reactivated 
whenever a stressful situation is present [47,52]. It modifies the expression of contractile 
proteins switching the expression of heavy myosin chain (HMC) from the more efficient but 
more energy expensive alpha to the slower but less energy consuming beta isoform, and 
increases the production of some humoral factors (brain natriuretic peptide, BNP ) and of 
several protective proteins (heat shock proteins, HSP). The cardioprotective pathway of the 
PI3K and Akt, activated during pre- and post-conditioning, is also activated by the fetal 
gene program supplying an antiapoptotic protection and leading to an overlapping between 
cardioprotection in chronic ischemia and ischemic preconditioning [52]. The metabolic 
component is mainly regulated by the enzyme pyruvate deydrogenase kinase (PDHK4) 
phosphorylating and inactivating pyruvate deydrogenase (PDH) and inhibiting the 
transformation into Acetyl-CoA that could enter the TCA; it is instead transformed into 
lactate by LDH allowing a continued production of ATP also in low oxygen settings. This 
activation of glycolysis, such as the dependent increase in GLUT1,4, in LDH and glycolytic 
enzymes is mainly controlled by the transcription factor HIF-1 that is upregulated in the 
settings of ischemia\hypoxia but also in non-hypoxic conditions such as during 
inflammatory states and tumours because its expression is increased through a cross-talk 
with NF-kB [53]. On the other hand hypoxia and inflammation are not completely separated 
conditions as showed by the induction of TLR4 and TLR6 by HIF-1 during hypoxia [54]. 
HIF-1 is composed by a constitutively expressed HIF-1 subunit and an oxygen-sensitive 
HIF-1 subunit, target under normoxic conditions of three prolyl hydroxilases 
1,2,3(PDH1,2,3), the hydroxylation allows the binding of the von Hippel-Lindau protein 
(VHL) and the consequent ubiquitination and proteasome degradation of HIF-1. On the 
contrary during hypoxia PDH2 activity is reduced with accumulation of HIF-1, its 
dimerization with HIF-1 and the expression of many target genes [55].  
The increased expression of HIF-1 causes at the same time a downregulation of 
mitochondrial lipid oxidation depressing the expression of the transcription factor PPAR 
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(possessing a DNA consensus motif for HIF-1)[56] and an upregulation of PPAR activating 
fatty acid uptake and glycerolipid biosynthesis so leading to lipotoxicity [57]. HIF-1 
stimulates also mitochondrial autophagy to rebalance the reduced oxidation with 
mitochondrial mass[ 58]. The stimulation of glycolysis by HIF-1 has an important role in 
sepsis because the phagocytes use huge quantities of glucose through glycolysis in the 
hypoxic environment of the inflamed tissues either for cell migration either for phagocytosis 
and bacterial killing [59]. The activity of HIF-1 is regulated by acetylation performed by 
CBP\p300 and inhibited by deacetylation by SIRT1. The inverse shift to mitochondrial lipid 
oxidation is controlled by SIRT1 which increases the expression of PGC-1 with 
simultaneous activation of both mitochondrial biogenesis and lipid oxidation through 
PPAR upregulation. SIRT1 and HIF-1 are reciprocally regulated so that in the 
hypoxic\inflammatory setting HIF- is activated while Sirt1 is decreased due to NAD+ 
scarcity so inhibiting HIF-deacetylation and inactivation while in normoxic environment 
HIF-is inactivated by oxygen-dependent prolyl hydroxylases PHD2 activated by SIRT1.  
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Figure 1. Metabolic switch. See text for explanation. 
Sirtuins are class III NAD+-dependant histone deacetylases (HDAC) targeting histones, 
transcription factors and enzymes regulating in this way gene expression and metabolic 
function in relation to the energy status of the cell [60-64]. They have been related to the 
regulation of metabolism, apoptosis and inflammation, to extending life span and to the 
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healthy aging. Sirtuins exist in seven forms with different subcellular localization: SIRT1,6,7 
present in nucleus, SIRT2 in cytoplasm, SIRT3,4,5 in the mitochondria. Because they are 
mainly regulated by the levels of NAD+, the AMPK that increases its concentration 
upregulates their expression while the DNA-repairing enzyme poly(ADP-ribose) 
polymerase 1 (PARP), activated whenever there is an oxidative stress and consuming for its 
activity high quantities of NAD+, downregulates sirtuin expression . SIRT1 is able to 
deacetylate and activate a series of transcription factors involved in many steps of 
metabolism (AMPK, FOXO, HIF-1, PGC-1, p53NF-κBPPAR and , LXR,FXR,ERR). 
Mitochondrial sirtuins are in a critical location to regulate metabolism and biogenesis of the 
organelles controlling oxidative phosphorylation (OXPHOS), intracellular Calcium and the 
production of ROS [65]. SIRT1 is also regulated via microRNA: microRNA34a 
downregulates its expression metabolically and microRNA199a in the hypoxic setting 
[66,67]. Statins have been showed to upregulate SIRT1 expression in endothelial cells 
contributing possibly to improve clinically endothelial function [68]. 
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Figure 2. Regulation of SIRT1 expression. See text for explanation. 
4. Transcriptional regulation of FFA transport, uptake and oxidation 
Transport, uptake and oxidation of FFA in the cell is a process tightly regulated by several 
transcription factors belonging to the nuclear hormone receptor superfamily. The nuclear 
receptors involved include the peroxisome proliferator-activated receptors (PPARs), liver X 
receptors (LXRs), farnesoid X receptor (FXR) and ERR (estrogen related receptor), which 
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bind and are activated by lipids, acting as sensors of endocrine signals and of dietary 
components and planners of the physiological response to nutrients. PPARs, the most 
important of them, are present in three types (alpha, beta and gamma), besides their action 
as lipids sensors, they are involved in the regulation of lipid and glucose metabolism, 
insulin sensitivity and modulation of inflammation (for review see [69-71]); their actions are 
partially overlapping with a certain degree of redundancy but they are not coincident. In 
elucidating the function of PPARs an important role has been played by the studies in 
genetically modified mice with overexpression or deletion of these nuclear receptors. PPARs 
are activated by endogenous ligands, FFA or their derivatives (arachidonic acid, 
eicosanoids, leukotrienes and oxidized lipoproteins) but there are also known exogenous 
ligands, used as drugs, for PPAR (fibrates) and PPAR (thiazolidinediones) or for both 
PPAR and (muraglitazar) [72]. 
The PPARs form heterodimers with retinoid X receptors (RXR) and bind to consensus DNA 
sequences in the promoter of the target genes, the PPAR response binding element (PPRE), 
formed by two hexameric nucleotides sequences separated by one base pair. In the absence of 
ligands the heterodimer binds with the co-repressors, blocking gene transcription; when 
activated by ligands, the complex, because of a change of conformation, releases the co-
repressors and recruits the co-activators and the RNA polymerase giving rise to transcription. 
PPAR are expressed mainly in tissues with high oxidative metabolism such as heart, muscle 
and liver. PPAR are expressed at high levels only in adipose tissue where they regulate the 
maturation and fat deposition in adipocytes so indirectly regulating, through the plasma level 
of FFA, the insulin sensitivity; they are however expressed at low level in many organs among 
which the heart [73]. Whereas PPAR and  share the ability to activate the transcription of 
proteins involved in FFA uptake, storage and oxidation, PPAR only activate the proteins 
involved in FFA oxidation. Also different are the effects on glucose metabolism: PPAR 
depress glucose oxidation whereas PPAR activate glycolysis (through PDHK4 activation) and 
glucose uptake; PPARactivate only glucose uptake [69,74]. 
PPAR\ are expressed in various tissues where they regulate lipid but even glucose 
metabolism. PPAR also regulate mitochondrial biogenesis through interaction with the 
PPAR coactivator 1 (PGC-1) network (see below)[74]. Because FAO takes mainly place in 
mitochondria (only the breakdown of very long chain fatty acids, subsequently converted 
to medium chain fatty acids and shuttled to mitochondria, takes place in the peroxisomes) 
there is a common regulatory mechanism for FAO and mitochondrial biogenesis 
controlled by PPARs and by the network of PGC-1. The PPAR mainly but also the 
PPAR have been showed, in several model systems, to modulate inflammation by 
transrepressing target genes of the transcription factors NF-κB, nuclear factor of activated 
T cells (NFAT), activator protein 1 (AP1) and signal transducers and activators of 
transcription (STATs) through a process called transrepression [75-77] so modulating the 
action of lymphocytes, macrophages and dendritic cells. This process has twofold 
importance, on the one side it may regulate the inflammation induced by tissue 
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macrophages, involved in the low grade inflammation and important in dysmetabolic 
conditions such as reduced insulin sensitivity, metabolic syndrome and atherosclerosis on 
the other side it may be of critical interest in regulating inflammatory reaction in sepsis 
[78]. LXRs and FXR heterodimerize also with RXR and are activated respectively by 
oxysterol and bile acids: both exist in the isoforms  and , contribute to lipid and 
lipoprotein regulation and modulate inflammation. In the regulation of FAO a 
fundamental role is also played by the orphan receptor (transcription factors without an 
identified endogenous ligand) ERR (estrogen related receptor) involved also in the 
regulation of mitochondrial biogenesis, gluconeogenesis and oxidative phosphorylation 
by interacting with PPAR and  and PGC-1 [79]. 
5. TG delivery: Lipolysis  
The amount of lipid in the myocardial cell is regulated by the balance between TG delivery to 
the heart through the VLDL- regulated by lipolysis- and the oxidation of TG in the 
myocardiocyte. Considering their importance in cellular signalling, lipid synthesis and as 
energy substrates, the level of circulating TG and FFA is tightly regulated [80]. Adipocytes are 
the only cells able to hydrolize TG giving rise to FFA and glycerol utilized by other tissues. 
This process is initiated by the adipose triglyceride lipase (ATGL) catalysing the hydrolysis of 
triglycerides to diglycerides followed by the hydrolysis of diglycerides to monoglycerides by 
the hormone-sensitive lipase (HSL) able also to catalyse the first phase and of monoglycerides 
to TG and glycerol by the monoglyceride lipase (MGL)[81-83]. ATGL deficiency is associated 
with fat deposition in all tissues indicating that ATGL is rate limiting in the catabolism of 
cellular fat depots [84]. Lipolysis is also regulated by perilipin , a protein coating the lipid 
droplets, that exposes TG of a lipid droplet to the action of the lipases [85].  
Many substances may activate physiologically and in diseases HSL, the more important 
enzyme for its sensitivity to the hormonal regulation but also for its action modulating 
adipogenesis and adipose metabolism [86]. Catecholamines acting through β1, β2 and also 3 
receptors coupled to a G stimulating (Gs) protein are the main stimulators of HSL; the alpha2 
receptors inhibit instead lipolysis through a G inhibitory (Gi) protein, this effect may be 
antagonized by administration of beta-blockers. Also natriuretic peptides are able to enhance 
lipolysis by activating guanylyl cyclase and increasing cGMP [83]. TNF IL1 and IL6 
increase HSL activity through the stimulation of several kinases of the MAP kinase cascade 
(janus kinases (JNK), p44\42 and extracellular signal-regulated kinase-1/2 ( ERK1/2) and the 
consequent increase in cAMP [87,88]. These kinases phosphorylate perilipin allowing HSL and 
ATGL to access and hydrolyse TG; this effect was prevented by metformin [89]. 
LPS may activate lipolysis by increasing ILs level, the demonstration however that the 
inhibition of TNF-alpha, IL1 and cathecolamines could not prevent lipolysis in endotoxemic 
rats, led to show a direct lipolytic action carried out by low-dose endotoxin [90].This action 
is not mediated by an increase in cAMP, activation of PKA or PKC or inhibition of NFkB but 
through phosphorylation of perilipin by LTR4 and ERK1/2. 
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The main inhibitor of lipolysis is insulin through the insulin-like receptor substrates 1and 
2(IRS-1and 2) that activate the phosphadityl inositol 3-kinase(PI3K) complex and 
phosphorylate and activate the phosphodiesterase 3(PDE-3) [80]. Insulin acts also via an 
Akt-Independent PI3K-dependent signalling pathway which modifies PKA 
phosphorylation of perilipin [91]. The reduction in insulin activity is responsible for 
increased lipolysis in diabetes and obesity together with the reduction in the insulin-
sensitizing activity of adiponectin [92] probably linked to the adipose tissue dysfunction 
described in sepsis [17,18]. Moreover adiponectin may reduce fat deposition in visceral 
adipose tissue increasing the deposit in the subcutaneous compartment through PPARγ 
upregulation [18]. The lipolytic activity is differently regulated in subcutaneous and 
visceral fat: the former, more important for the basal activity, is more sensitive to the 
antilipolytic action of insulin, the latter is mainly activated during hormonal stimulation 
and provides FFA directly to the liver through the portal circulation in physiological and 
pathophysiological situations. In sepsis seems to be present a failure of adipocytes 
differentiation leading to a decreased storage ability of the subcutaneous tissue allowing 
FFA to be accumulated in visceral fat (with an increase in the metabolic and 
cardiovascular risk) and in organs giving rise to lipotoxicity for the concomitant reduction 
of FAO [18]. Lipolysis is increased in sepsis [14] due to a raised activity of the lipases of 
the adipose tissue, mainly the HSL, because of the increased plasma level of 
catecholamines, ILs and natriuretic peptides and the reduced activity of insulin and 
adiponectin (fig 3). 
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Figure 3. Lipolysis in sepsis. See text for explanation. 
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5.1. Lipoprotein metabolism in sepsis  
Sepsis and inflammation reproduce an atherogenic picture of serum lipoproteins [93] with 
an early reduction -preceding even the change in leukocytes- of total HDL- and LDL-
cholesterol, an increase in VLDL and TG justified by augmented liver synthesis and 
lipolysis, a reduction in HDL phospholipids compensated by an increase in VLDL 
phospholipids. 
5.2. HDL in sepsis 
Until recently HDL were considered as devoted only to reverse cholesterol transport (RCT), 
a process through which the cholesterol is transferred from the cells to the acceptor 
apolipoproteinA-1 by the specific transporter A binding cassette 1(ABC1) and delivered to 
the liver where it is finally secreted and eliminated in the bile, the only way of its removal 
from the body. The recent application in this field of the Gel Filtration Chromatography 
based proteomics revealed that HDL contain not only apo-A1, apo-A2 and some enzymatic 
and transfer protein involved in cholesterol transport but more than 50 other associated 
proteins [94]. Many of the proteins isolated carry out functions completely different from 
RCT belonging to the complement proteins (C3,C1 inhibitor, factor H) and to serine protease 
inhibitors (SERPIN) [95-97]. The recent attainments point to an important role of HDL in 
immunity and in the modulation of the inflammatory response but they are also involved in 
a lot of disparate functions ranging from glucose metabolism to endothelial protection 
displaying also an antithrombotic action (for review see [98,99]). Of main importance in 
sepsis is the property of HDL to bind and neutralize LPS, mediated through its content in 
phospholipids. 
HDLs may carry out anti-inflammatory actions in many ways: they downregulate the 
proinflammatory transcription factor NF-kB through a not yet completely understood 
mechanism -probably by the reduced degradation of Inhibitor kappa-B-a (IkB-a) [100]-, 
moreover they reduce the expression of the adhesion molecules CD11b and MCP-1 on 
human monocytes [97] and may curtail TNF-alpha production and upregulate IL-10 
production by lymphocytes. The normal anti-inflammatory function of HDLs turns into a 
proinflammatory one during the acute phase reaction (APR) when they become 
dysfunctional [101]. The reasons for this change are manifold: there is a reduction in ApoA-1 
levels, partially substituted by serum amyloid A apolipoprotein (Apo-SAA), their size is 
smaller because of a reduced activity of lecytin cholesterol acyl transferase (LCAT), enzyme 
deputed to esterification of cholesterol that allows the enlargement of HDL, HDLs become 
poorer in the antioxidant enzymes paraoxanase [102,103]. 
The interference with the function of the inflammatory cells may be direct or mediated by 
the effect of the HDL on the reduction of cellular cholesterol and of cholesterol-enriched 
microdomains or rafts of their plasma membrane; this is also showed by the increased 
lethality and inflammatory response observed during sepsis in transgenic null mice for 
critical receptors involved in cholesterol efflux as SR-BI and ACBA1 [104]. 
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Figure 4. Relationships among mitochondrial dysfunction, metabolism, and contractility. See text for 
explanation. 
HDL may bind and inactivate LPS mainly through their phospholipid component [105,106], 
in sepsis and inflammation because of the HDL reduction their LPS inhibiting function is 
assumed by the VLDL phospholipids. 
Also the endothelial function is modified through an increased production of nitric oxide (NO) 
by the stimulation of endothelial nitric oxide synthase (eNOS) mediated by the activation of 
the protective PI3K\Akt pathway leading to vasodilation, antiadhesion and anti-inflammatory 
effects [107]. A similar cardioprotective and antiapoptotic action of HDL have been shown 
through the activation of Stat3 mediated by sphingosine 1 phosphate (S1P), one of their 
common component [108]. The recombinant HDL(rHDL) or HDL mimetics, currently under 
clinical trial, are provided with the same actions attributed to the HDL [109,110]. The level of 
total, HDL- and LDL-cholesterol is decreased in septic and critically ill patients, as well as in 
experimental animals infused with LPS and proinflammatory cytokines and the decrease is 
negatively related to IL6 and TNFa concentrations [111]; HDL reduction is also related to 
mortality and severity of the disease [105,106]. 
The reduced level of serum HDL and cholesterol in sepsis is explained by a reduced RCT 
[112] mediated by the LPS-induced downregulation of the scavenger receptors SR-B1 and 
ABCA1 [113]. The sequestration of the cholesterol into the cell may be useful in the short 
term, due to the increased delivery to the immune cells, but harmful in the long run because 
of the decreased delivery to the steroidogenetic and liver cells and to the atherogenic picture 
it induces. 
5.3. VLDL  
VLDL are a circulant reservoir of TG and FFA able to activate PPAR and [ In clinical 
sepsis and experimental endotoxemia the serum level of VLDL, FFA and TG is increased 
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due to the upregulation of the hepatic synthesis of TG, FFA and apoB, to the increased 
lipolysis, decreased lipid oxidation and inhibition of LPL [103]. The increased lipolysis in 
sepsis is due to the activation of the hormone-sensitive lipase (HSL) by catecholamines 
acting through PKA stimulation and cAMP increase. To the increased lipolysis contribute 
also the increased level of ILs, of natriuretic peptides and the reduction in insulin and 
adiponectin activity (see paragraph on lipolysis).  
Feingold, in mice, showed that LPS reduced in the heart, diaphragm and kidneys [115-117] 
the levels of many enzymes involved in the fatty acid metabolism (FATP1,MCAD, CD36, 
CPT1 etc) through the reduced expression of many transcription factors: PPARand 
LXR, FXRpregnane X receptors and their coactivators PPAR coactivator 1and 
(PGC-1andsteroid coactivator receptor 1 and 2 (SRC1-2) and ERR. The 
downregulation of the nuclear receptors can be reproduced by IL-1 and TNF 
administration. Maitra and colleagues described an important role for IRAK1, a signalling 
component downstream of TLR4, in the downregulation of these transcription factors in 
sepsis showing that IRAK1 -/- mice were protected against alterations in lipid metabolism 
[118]. Because all these factors are deacetylated and activated by SIRT1 their 
downregulation in sepsis may play an important causative role [68] (see the paragraphs on 
metabolic switch and mitochondrial dysfunction). 
The increase in VLDL during sepsis, traditionally considered as a reaction mobilizing lipid 
stores to delivery an increased amount to the immune cells, may also have a protective 
meaning: the increased level of serum VLDL and of their content in phospholipids can 
substitute for the HDL in binding and neutralizing LPS [119,120].  
6. Mitochondrial dysfunction play an important role in septic 
cardiomyopathy  
Mitochondrial dysfunction -present in sepsis but also in many other pathological states such 
as chronic heart failure, diabetes mellitus, metabolic syndrome and several 
neurodegenerative diseases- is a syndrome characterized by a picture of reduced oxygen 
consumption, ineffective ATP production, increased accumulation of ROS and calcium in 
the organelle leading to the opening in the internal mitochondrial membrane of a high 
conduction pore allowing the entry of solutes until a molecular weight of 1.500, with 
mitochondrial swelling, collapse of the electron gradient, release of proapoptotic proteins 
and death of the organelle (mitoptosis) followed by mitophagy: this phenomenon called 
mitochondrial permeability transition pore (MPTP) has an important role in sepsis and its 
inhibition may experimentally improve septic myocardial dysfunction [28,121-123]. 
Mitochondrial functionality is regulated by the equilibrium between de novo mitochondrial 
formation (mitochondrial biogenesis) and mitochondrial autophagy (mitophagy), frequently 
preceding whole cell autophagy. This latter process, taking place only in deenergized 
organelles, is very important for cell survival because it allows the elimination of 
dysfunctional mitochondria, producing too much radical oxygen species(ROS) and assures 
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the high quality of the mitochondria provided with a high membrane potential and resistant 
to MPTP [124]. Moreover autophagy has been shown to be protective in ischemia-
reperfusion injury (IRI) and inflammation by inhibiting the exposition of mtDNA and the 
consequent activation of the inflammasome NALP3 [125]. Autophagy involves a complex 
molecular machinery including more than 30 Atg (AutophaGy-related) proteins and 50 
lysosomal hydrolases [126]. 
The mitochondrial biogenesis is orchestrated by PPARand \by the ERR and above all 
by the network PGC-1PGCand PGC-1 related coactivator (PRC), factors enriched in 
tissues with high oxidative capacity (heart, muscle, brown adipose tissue and kidneys) and 
highly inducible by starvation, exercise and cold acclimation (126-128); PGC-is also 
induced by Ils [129]Mice with single deficiency in PGC-1 or PGC- display only minimal 
alteration under nonstressed conditions and have a normal mitochondrial mass [130,131] 
whereas mice with double deletion of both PGC-1 forms died shortly after birth with small 
hearts, bradycardia, intermittent heart block, and a markedly reduced cardiac output [132], 
allowing to think that one isoform may compensate for the other. Mitochondrial 
biogenesisto take place needs the transcription of the genes controlled by mitochondrial 
DNA, a process activated by the mitochondrial transcription factor A (Tfam), a nuclear-
encoded transcription factor essential for replication, maintenance and transcription of 
mitochondrial DNA [133]. The majority of the genes codifying mitochondrial proteins are 
however present in nuclear DNA and are activated, such as Tfam, by the nuclear respiratory 
factors 1 and 2 (NRF1 and NRF2). PGC-1 coordinates the function of NRF1, NRF2 and Tfam, 
regulating mitochondrial biogenesis and, through the complex PPARs-ERRs, controls FAO 
such that a prompt adaptive response to physiological events as cold acclimation, exercise, 
starvation etc may be possible with selection of the most suitable level of FFA oxidation 
needed in the particular situation. 
Cardiac contractile activity is linked to the mitochondrial biogenesis because an increase in 
intracellular calcium increases the expression of PGC-1 via calcineurin (CaN) -activating also 
PPARpromoter and FAO- and Ca-calmodulin dependent kinase (CaMK), a process 
requiring cAMP response element-binding protein (CREB)(126,133): in this way the contractile 
activity is strictly linked to the metabolism and to the mitochondrial oxidative function. 
PGC-1 expression is also controlled hormonally by tyroid hormones (TH), metabolically via 
adrenergic system and cAMP, by AMPK and p38 MAPK through phosphorylation [126,133] 
and by eNOS-produced NO. The cellular mitochondrial content is proportional to the 
energy requirement [75], mitochondrial biogenesis is therefore controlled by the two main 
energy sensors in the cell: Sirt1(silent mating type information regulator 2 homolog 1) and 
AMPK act coordinately to control PGC-1 activity respectively through deacetylation and 
phosphorylation. Sirtuins are class III histone deacetylating enzymes supplied by AMPK 
with the adequate level of the NAD+, essential activator of Sirt1 that in turn deacetylates 
PGC-1 and activates its gene expression [75]. Sirt1 is also an important in vivo regulator of 
mitophagy by deacetylation of the autophagy genes Atg5, Atg7 and Atg8 [134], linking this 
protective mechanism, devoted to the clearance of depotentiated mitochondria, with PGC-
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1a mediated biogenesis. For biogenesis to occur it is necessary mitochondria undergo the 
processes of fusion and fission regulated respectively by mitofusins (Mfn1-2) and by 
dynamin-related protein(DRP1 and OPA1) [126]. 
The first description of mitochondrial dysfunction in sepsis dates back to 1970’ [135,136], but 
the initial studies were not reliable due to inadequate techniques to test mitochondrial 
function. More recent studies however linked the altered oxygen utilization and ATP 
production in sepsis to mitochondrial dysfunction (137,138), even though there are substantial 
differences among the sepsis model induced by LPS administration in which is present a 
widespread mitochondrial damage and the CLP model characterized by a less evident 
mitochondrial pathology because damaged organelles undergo autolysis and autophagy [139]. 
Several alterations have been described in mitochondria in experimental and human sepsis 
both morphological (swelling, destruction of cristae, decreased electron density, breaks in 
membrane and altered outer membrane integrity) and biochemical (release of cytochrome c, 
decreased mtDNA copy number, reduced activity of Complexes I and III) [28,140,141]; their 
extent has been related to outcome [142]. Several studies showed an initial increase of 
mitochondrial activity in sepsis, followed by a reduction. Singer [132] hypothesized that, after 
a metabolic stimulation of mitochondrial function. caused by the excessive inflammatory 
response, in the successive phase there is a metabolic downregulation determined by the 
mitochondrial dysfunction. In this latter phase a stimulation of oxygen consumption (VO2) 
would be harmful because it forces mitochondria, adapted to a reduction of metabolism, to 
overwork without being prepared for it. The restorative phase of sepsis is linked to the 
activation of mitochondrial biogenesis; also LPS may have a role in inducing this process 
[140,143]. The absence of relevant cell death by apoptosis or necrosis in parenchymatous 
organs and the ability also of the tissues with less regenerative capacity to recover led to think 
that multiple organ dysfunction syndrome (MODS) were related mainly to a functional 
compromise mediated by endocrine and metabolic alterations and provided with a protective 
role [144-146]. In sepsis a paradoxical increase has been observed, in some tissue, in blood 
oxygen saturation [147], related to outcome and linked to an altered mitochondrial oxygen 
utilization (cytopathic hypoxia) [148], which has been attributed to nitric oxide (NO) 
overproduction by mitochondrial nitric oxide synthase (mtNOS) [149,150] or other NOS 
isoforms: NO competitively inhibits oxygen binding to cytochrome c oxydase (COX) 
determining a tonic inhibition of mitochondrial oxygen consumption, reversible on inhibiting 
its excessive production [151]. The exact role of NO inhibition by COX in vivo in physiologic 
and pathologic conditions is however an unsettled problem [152]. Other gaseous molecules 
share with NO the ability to interact with COX, to inhibit it competitively and to regulate at 
this level the body oxygen consumption [153,154]; they are called gasotransmitters and include 
carbon monoxide (CO) and Hydrogen Sulphide (H2S), this latter molecule was first shown 
able to induce experimentally in mice, but not in pigs and superior mammals, a particular state 
of depression of the metabolism and of the resistance to hypoxia, called “suspended 
animation” (155]. A similar observation has been made with NO and CO in Drosophila 
[156,157]. Exploiting this property of gasotransmitters in the treatment of myocardial and 
cerebral hypoxia\ischemia is tempting, considered also the limitations of the current treatment 
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with hypothermia of the hypoxic organ injury, even though they also have a high toxicity 
[158]. To the picture of metabolic hibernation may contribute, besides NO, also CO and H2S 
increased during sepsis [159-161].  
In addition to the antagonism against COX the higher levels of NO, in presence of an 
increased oxidative stress, by reacting with superoxide, may further injure mitochondria 
determining the formation of the toxic peroxynitrite able to damage the Complex I and III of 
the ETC, the membrane lipid and mitochondrial and nuclear DNA. The available data 
however cannot be explained only by this mechanism; the metabolic ebb phase, coincident 
with CARS and silencing of proinflammatory genes, is characterized by a profound state of 
mitochondrial depression, reduced oxidative metabolism and oxygen consumption leading 
to a state of metabolic hibernation responsible for the depressed cell function during MODS 
in sepsis; mitochondrial depression is however completely reversible on recovery from 
sepsis. Recently Schilling and colleagues showed that LPS administration through TLR4 
stimulation may induce a fuel switch from preferential myocardial use of lipid to glycolysis, 
similar to the one observed in the failing heart, with decreased mitochondrial oxidation, 
lipid accumulation within them and a suppression of the genes encoding PGC-1 and : the 
genetic overexpression of PGC-1 may restore mitochondrial function independently of the 
inflammatory response [162]. Smeding and colleagues [163], on the other hand, observed 
that the sirtuin activator resveratrol protect mitochondria in a mice model of CLP improving 
myocardial dysfunction, preserving energy production but without improving survival. At 
this point some question should be raised: could we think that the mitochondrial 
dysfunction is a reversible event even in the presence of a continuing sepsis? Which may be 
the correct link and the ordinated succession among all the alterations described? 
We try to reconstruct the successive steps leading to mitochondrial dysfunction and to 
metabolic hibernation in sepsis (fig. 5). The first step is the hypercatabolic phase with the 
transient activation of mitochondrial oxidative phosphorylation (OXPHOS) activated by the 
acute hormonal stress response in the very early phase, with increased oxidative and 
nitrosative stress damaging ETC and inducing a downregulation of many of its proteins. 
Immediately after, in the inflammatory setting of sepsis, occurs the shift to glycolysis and the 
activation of mito autophagy. SIRT1 is rapidly deactivated by the reduced function of AMPK, 
the decreased NAD+ levels due to the activation of PARP and by the increased expression of 
miR199a [66]. The stimulation of this enzyme in sepsis was first showed by Fink [148]; recently 
Zhang and colleagues, after LPS administration in mice, observed that the plasma levels of 
ATP, SIRT1 and AMPK decline precipitously after 10’ and remain below the detection level for 
up to 12 h while HIF-1 increases contemporarily along with an increase in mitochondrial 
autophagy. Importantly all these effects are absent in wild type mice treated with resveratrol 
but not in Sirt1 liver knockout mice [164]. This study further confirm the critical role of SIRT1 
that would be downregulated in sepsis for many causes: increased HIF-1 expression, increased 
miR199a expression, drastic reduction of NAD+ by activation of PARP consuming it and 
reduced activity of AMPK supplying it. The main consequence of these modifications are the 
reduced deacetylation by SIRT1 and phosphorylation by AMPK of PGC-1, also PGC 
seems to be reduced in muscle during sepsis [162,165] making impossible a compensation. The 
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role of PARP has also been showed by Soriano in the setting of human septic myocardiopathy 
[166], where the degree of myocardial compromise related well with the staining for the 
product of activated PARP [poly(ADP-ribose) (PAR)], and in many experimental model of 
cardiovascular diseases[167] in which PARP inhibitors provide significant benefits. 
Interestingly the metabolic hibernation in sepsis according to our hypothesis has a different 
starting point from the true mammals hibernation in which the scarcity of nutrients leads to 
increased levels of NAD+ and AMP with AMPK and SIRT1 activation and deacetylation of 
clock protein BMAL1 and the opposite switch from glucose to lipid metabolism [168]. The 
connection between bioenergetics impairment and inflammation in sepsis has also been 
studied by Liu and colleagues [169-170] that underline the role of Sirt1 in reprogramming 
immune response through the silencing of the proinflammatory genes and the coordination of 
the metabolic response. In the experimental setting many attempts have been made to treat 
mitochondrial dysfunction by supplying substrates, cofactors, mitochondrial-targeted 
antioxidants, scavengers of mitochondrial ROS and membrane stabilizers displaying 
improvements at many levels: ATP production, reduced production of ROS in mitochondrial 
ETC, reduction of apoptosis and prevention of MPTP opening [171-174]. Apoptosis may also 
have a role in septic mitochondrial dysfunction as it has in CHF. Lancel and colleagues 
demonstrated in cardiomyocytes isolated 4 hours after endotoxin injection in rats, an increase 
in the release of caspase-3, -8, and -9-like activities, associated with destruction of the 
sarcomeric structure and cleavage of components of the cardiac myofilament [175]. 
Simvastatin, whose use has been proposed in sepsis, may protect against apoptosis induced by 
Staphylococcus aureus alpha-toxin [176]. 
NF-kB PGC-1
SIRT1
HIF-1
activation
PARP
activation
NAD+
PPAR, ERR
LXR, FXR
AMPK
Sepsis, LPS
Inflammation
Increased oxidative
and nitrosative stress
Prolonged depression of mitochondrial biogenesis and function
 
Figure 5. Mitochondrial dysfunction in sepsis. See text for explanation  
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6.1. Cardiac function in sepsis  
The pathogenesis of the myocardial dysfunction in sepsis is not definitively explained and is 
probably caused by a myriad of alterations. The morphological picture recognized in sepsis 
was formerly considered unspecific but more recently many interesting alterations have 
been described even though certainly some of them are not the cause but the consequence of 
the acute cardiac damage. Beside not specific alterations such as cell edema, the already 
described mitochondrial lesions, damage of cytoplasmic membrane and myofibrils, 
inflammatory cells infiltration [139,177], more definite biochemical and microscopic changes 
have been observed with lipid infiltration [178], increased deposits of glycogen and 
increased levels of glucose uptake, GLUT1 and GLUT4 [141], increased sarcolemmal 
permeability [179], disruption of sarcolemmal dystrophin and beta-dystroglycan [180]. 
6.2. Hemodynamic pattern  
Parker and colleagues in 20 p. in septic shock [181], adequately resuscitated, with the 
combined use of radionuclide-gated cardiac cineangiography and thermodilution observed 
important differences in the hemodynamic pattern of survivors and non survivors. Both 
groups had a hyperdynamic pattern with high cardiac index (CI) and low systemic vascular 
resistance (SVR) but survivors had an important LV dilatation and a reduced left ventricle 
ejection fraction (LVEF) normalizing in 7-10 days while non survivors paradoxically showed 
higher LVEF but did not show ventricular dilatation. On the basis of these data Parker 
thought that LV dilatation were an adaptive mechanism apt to increase systolic stroke 
through a better utilization of Starling mechanism (early preload adaptation). Successive 
studies by echocardiography have not confirmed however a significant LV dilatation while 
observing an altered biventricular relaxation and a systolic dysfunction of the right ventricle 
in 41% of the p, isolated or in conjunction with a LV dysfunction [182-185].The apparently 
better cardiac function in non survivors is currently perceived as a consequence of the 
persistent septic hemodynamic pattern with decreased SVR causing higher CI and LVEF, 
both being heavily load-dependent indexes [186]. A LV depressed contractile performance is 
constant in human and experimental sepsis [187] if related to pre and after-load, it is 
explained by the global ventricular hypokinesia observed in 60% of the p. in septic shock 
[188]: the impairment of LV contractility may be unravelled also by the reduction of CI in 
response to norepinephrine infusion [181]. A feature of septic myocardiopathy is the 
absence of the increased LV filling pressure, characteristic of cardiogenic shock, due to the 
dysfunction of the right ventricle [189] and to the slightly increased LV compliance [190]  
Currently the hyperkinetic syndrome (small left ventricle, supranormal ejection fraction, 
tachycardia, high cardiac index) had a 100% mortality rate [186]. In contrast with the 
majority of other reports Jianhui and colleagues ( describe in mice infused with 
intraperitoneal LPS and studied with left ventricular (LV) pressure-volume catheters 
significant drop in LV stroke volume with a significant decrease in LVEF with no apparent 
change in LV afterload. load-dependent indexes of LV function were markedly reduced at 6 
h, including EF, stroke work, and dP/dtmax. In contrast, there was no reduction of load-
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independent indexes of LV contractility leading the authors to think that the depressed 
contractility after LPS infusion was due only to loading conditions [191]. 
6.3. Pathophysiological mechanism 
The infusion of small doses of LPS in healthy volunteers may reproduce the features of the 
septic circulatory dysfunction with low systemic resistances and a depressed myocardial 
function [187]. The mechanism of the altered myocardial function, at first attributed to a 
myocardial depressant factor (MDF) [192], began to be understood when in 1985 Parrillo 
[193] showed that the serum of septic humans during the acute phase may depress the 
contractile function of isolated myocardiocytes; this effect may be prevented, as 
subsequently demonstrated by Kumar, by immunoadsorption of IL-1 andF 194 Ils 
may cause myocardial depression both directly or through the NO produced by the 
induction of iNOS [195]. In the recent years the focus of the research has been turned on the 
upstream mediators of ILs, the TLRs, that have been shown to be main mediators of 
myocardial damage in sepsis models of both LPS infusion and CLP and in human sepsis 
[196]. Their effect as already seen is due to the release, consequent to the inflammatory 
reaction and to the tissue damage, of DAMP further increasing tissue injury. The main TLRs 
types expressed in the heart are TLR2 (recognizing lipoteichoic acid) and TLR4 (LPS 
receptor) but also TLR 3 and 9 are present [196]. Both TLR2 and TLR4 have been 
demonstrated as essential mediators of the septic myocardial damage: in mice with their 
genetic deficiency there was a better preservation of cardiac function and a decreased 
mortality[14,197,198]. Also TLR5, receptor for bacterial flagellin, TLR9 (endocellular 
recognizing bacterial DNA) and very recently TLR3, endocellular receptor recognizing viral 
double stranded RNA, have been showed to play a deleterious role in mediating cardiac 
dysfunction in sepsis [199,200]. This depression of myocardial function is linked to the 
response of myocardiocytes to the release of alarmins with increased production of pro- and 
anti-inflammatory ILs, of chemokines and cell adhesion molecules [196]. The connection 
with the reduced contractile function is represented by the increased production of the 2 
small calcium regulated molecules (S100A8 and S100A9) that have been showed with 
coimmunoprecipitation, able to suppress calcium flux interacting with the RAGE receptor 
[201]. TLRs lead to iNOS stimulation, NF-kB upregulation and to increased expression of 
TNF, IL1, IL6, IFN chemokines and cell adhesion molecules responsible for the cellular 
damage but also for the initiation of the reparative process [202]. The inflammatory reaction, 
as already seen, is modulated by the appearance of LPS tolerance and proinflammatory 
genes silencing. As already said, a long term stimulation with LPS or a TLR4 ligand (such as 
HMBG1) may induce preconditioning [9] and in decreased brain infarct size in mice that 
were subjected to focal cerebral ischaemia/reperfusion injury [10].  
In sepsis there is an increased production of NO by inflammatory cells infiltrating 
myocardium but also by endothelial and smooth muscle vascular cells due to stimulation of 
iNOS. The increased NO production causes an impressive vasodilation, a reduced 
sensitivity to the vasoconstrictors and an increase in capillary permeability. NO has also a 
depressive action upon the myocardium mediated by the production of cGMP. In fact NO 
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behaves as a double-edged sword because if on one hand depresses myocardial contractility 
increasing cGMP production, reduces oxygen consumption by antagonizing COX and may 
induce apoptosis on the other hand it supports relaxation normalizing the stiffness of the 
septic myocardium, antagonizes the action of the increased endothelin and has a 
cardioprotective effect through the induction of preconditioning [203]: unselective 
antagonism of NOS with NNMA is harmful in sepsis because even though it raises blood 
pressure it decreases cardiac, hepatic and renal blood flow [204]. Many other alterations 
have been described in septic myocardium: an altered phosphorylation of Troponin I (TnI) 
in serin 23-24 by Protein Kinase A (PKA), activated by receptors or an upregulation of 
Protein Phosphatase 2A (PP2A). dephosphorylating TnI [205,206]. The cause of the 
increased phosphorylation of Tn seems to be the increased -adrenergic activity during the 
early phases of sepsis followed by a reduction during the late phase characterized by the 
hypodynamic cardiac pattern. A calcium leak from sarcoplasmic reticulum has been also 
described in sepsis similar to that observed in CHF and determined also by PKA activation 
and increased phosphorylation of the calstabin, a protein maintaining in its stable form the 
sarcoplasmic ATPase assigned to the re-entry of Calcium in sarcoplasmic reticulum after 
systole [207,208]. Such an alteration could justify both diastolic dysfunction due to the 
diastolic calcium leak and the systolic dysfunction showing itself in the late phase as 
expression of depletion of Calcium reserves. An altered autonomic tone with increased in 
sympathetic activity in the early phases of sepsis and decreased heart rate variability has 
been described [209]. 
Levy and colleagues [141], as already seen, showed in the septic myocardium important 
alterations (reduced cardiac performances, increased glucose uptake, increased myocardial 
glucose transmembrane transporters GLUT1 and GLUT4, increased deposits of glycogen). 
Because these modifications have been described as typical of the myocardial hibernation, 
Levy proposed that this latter may take part in the septic cardiac dysfunction. It is however 
debatable that the "true" ischemic myocardial hibernation is responsible for cardiac 
dysfunction in sepsis for several reasons: 1)myocardial hibernation is no longer considered 
as a down-regulation of the contractile and metabolic activity aiming at reducing the oxygen 
consumption and at adapting it to the reduced blood supply (smart heart hypothesis). It is 
instead attributed to repetitive episodes of myocardial stunning [210] 2) reduced myocardial 
perfusion has never been demonstrated in sepsis [211], the biochemical modifications 
showed in septic myocardium are not features of hibernating myocardium, they are instead 
present in the fetal heart and also in the stressed myocardium as expressions of the 
reactivation of the fetal gene program [47,52]. The alterations described in septic 
myocardium would therefore be unspecific and their presence could be explained in sepsis 
by the inflammatory state that characterizes it. The picture of metabolic hibernation present 
in sepsis should therefore be separated from that of the true myocardial ischemic 
hibernation whose existence, in our opinion, has not been convincingly demonstrated in 
sepsis. 
Myocardial injury in sepsis is also shown by the increase of many markers such as 
troponin (Tn) and natriuretic peptides. Whereas Tn I and TnT levels are good indicators 
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for cardiac function in sepsis relating well with left ventricular dysfunction and a poor 
prognosis, BNP is related to the outcome but only weakly with cardiac filling pressures 
[212]. A high level of BNP >144 pg/ml predicts cardiac dysfunction with high sensitivity 
(92%) and high specificity (86%)[213]. BNP upregulation takes part in the reactivation of 
the fetal gene program and its production has been shown to be increased during 
inflammatory processes related to the ability of inflammatory ILs and of p38MAPK to 
increase its secretion increasing its promoter activity [214]. Differently from the regulation 
of the similar molecule ANP, BNP secretion is regulated more by inflammation than by 
hemodynamic compromise. 
7. Metabolic dysfunction in chronic heart failure 
The chronically failing heart is certainly energy-deprived [215], as has been ascertained by 
studies with 31P magnetic resonance (MR) spectroscopy [216] showing the reduced 
phosphocreatine: ATP ratio, important index of the energetic state of the heart correlated 
with the indexes of systolic and diastolic function [217]. The cardiac contractile function is 
inextricably linked to the metabolic function so that the alterations of cardiac metabolism 
observed in chronic heart failure must affect also the contractile function. As heart failure 
progresses mithocondrial respiration is gradually compromised preventing that a normal 
level of FAO may take place. In samples taken from explanted hearts, during 
transplantation in patients with advanced heart failure, the level of the enzymes of FAO 
was low compared to the non-failing hearts [218]. The reduction of mitochondrial 
biogenesis and of FFA oxidation in the advanced phase of CHF is, as already seen, caused 
by the reactivation of the fetal gene program through the upregulation of HIF-1 and the 
downregulation of PPAR, \ERR, of SIRT1 and of the PGC-1network 
demonstrated in myocardial samples of patients with end-stage heart failure compared 
with explanted non failing hearts [219]. The expression of these transcription factors and 
coactivators is reduced in pathological hypertrophy and heart failure whereas it is 
upregulated in physiological forms of hypertrophy related to postnatal growth or exercise 
training [220] so furnishing a precise boundary between physiologic and pathologic 
cardiac growth. Interestingly also a constitutive cardiospecific overexpression of PGC-1 
in mice (MHC–PGC-1 mice) may damage the heart leading to myocardiopathy with 
uncontrolled mitochondrial proliferation but only in the neonatal period, whereas the 
overexpression in adult mice provoked only modest mitochondrial proliferation [221,222]. 
PGC-1 -\- mice show a reduced capacity both of exercising and of acclimating to cold 
temperature [223]. 
The fetal gene program is mediated by an incompletely known but modified expression 
of various microRNA [224-226]: Sucharov described that changes in the expression level 
of miR 100 and 133b contribute to the regulation of the fetal gene program [225]. The 
reduced expression of SIRT1 underlies the depressed mitochondrial biogenesis and FAO 
in the chronically failing heart. SIRT1 seems to be expressed at higher levels in the first 
phases of hypertrophy, the first physiologic response to the overload of the heart, as a 
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response to the stressing event inducing it but begins to be downregulated when PARP 
activation takes place, due to the increased oxidative stress [227], reducing NAD+ 
availability. The reduction in SIRT1, provided with an antiapoptotic function, and the 
compromised mitochondrial activity may contribute to the increased cellular death in 
chronically failing myocardium [228,229]. Overall we may conclude that some 
similarities exist between the metabolic and morphological alterations observed in sepsis 
and CHF. 
8. Cardiac lipotoxicity in chronic heart failure and sepsis 
In 1858 Virchow first reported intramyocyte lipid accumulation in patients with congestive 
heart failure, he referred to it as "lipid atrophy" of the myocardium [230]. At present the 
presence in the myocardial cell of neutral lipid droplets is ascribed to the altered glucose 
and lipid metabolism and to a mismatch between lipid delivery and oxidation. In normal 
conditions TG are stored only in adipocytes, under the control of PPAR with minimal 
presence of lipids in other tissues [231,232]; in this way adipocytes play indirectly a key role 
in the control of systemic glucose, lipid homeostasis and insulin sensitivity through the 
regulation of the serum level of FFA. In congenital lipodystrophy, a disease characterized by 
a decreased capacity of lipid storage in adipose tissue, the non-adipose organs accumulate 
TG and there is a premature cardiomyopathy [233]. When an overload of cellular FFA takes 
place caused by increased lipolysis or increased uptake (evident in clinical settings as in 
diabetes, in the experimental CD36 and LPL overexpression [234,235] or in settings of 
reduced FAO), lipid deposits in the myocardium and other organs may occur giving rise to 
the already seen phenomenon of lipotoxicity [236]. The contractile dysfunction caused by 
intramyocardial lipid accumulation is mediated at least partly by an altered expression of 
Sarco/Endoplasmic Reticulum Calcium ATPasi (SERCA2) as showed in specimen taken 
intraoperatively in patients with aortic stenosis and metabolic syndrome [237]. A diastolic 
dysfunction is also present, frequently preceding the systolic derangement and associated 
with interstitial fibrosis. Lipid accumulation is present in the heart of patients with CHF 
mainly in people with obesity, diabetes and metabolic syndrome. The relationship is 
bidirectional, insulin resistance predisposes to CHF and CHF increases insulin resistance. A 
reduced insulin sensitivity is observed in many patients with CHF, moreover its presence 
represents a risk factor for the eventual development of heart failure. Therefore the lipid 
accumulation alone without a reduced insulin sensitivity, obesity or metabolic syndrome can 
cause lipotoxicity. The importance of the cardiac isolated steatosis has been showed in the 
experimental context by demonstrating that myocardial overexpression of both PPAR and  
is associated with lipid accumulation and contractile dysfunction [238,239] probably because 
they stimulate more the uptake than the oxidation of FFA; moreover the PPAR activator 
fenofibrate can prevent the contractile dysfunction and the reduced calcium sensitivity in a rat 
model of LPS infusion further demonstrating the tight relationships between metabolic and 
contractile compromise [240]. Lipid deposits in the cardiomyocytes as TG in CHF is only a 
marker of an imbalance between the uptake and oxidation of FFA and not necessarily relates 
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to toxic lipid byproducts formation. The chronic accumulation of neutral lipids is probably not, 
per se, immediately harmful for the myocardial cell in CHF but represents a mechanism of 
defence against the excess of the FFAs, more metabolically reactive, reaching it [241]. In the 
long term however lipid store may behaves as a time bomb because when a critical point is 
reached, either by accumulation of excessive quantity of lipid or by some event triggering an 
increased FAO, the accumulation of toxic byproducts such as ceramides, diacylglycerol, fatty 
acyl-CoAs and acyl-carnitine ensues damaging the myocardial cell.  
The lipid accumulation in the heart during infections has been described since the ’90 of the 
last century [242] however the only complete study in sepsis is the article by Rossi and 
colleagues [169]. They showed in septic myocardium an increased staining by the dye oil 
red O, specific for lipid, and attributed it to an altered metabolism of the myocardium.  
These alterations are the morphological expression of the switch from lipid to glucose 
utilization in a setting in which lipolysis is increased and FAO reduced by PPAR 
downregulation and by acute mitochondrial dysfunction. 
Very little is known about the significance of lipid accumulation in the septic myocardium; 
initially interpreted as a degenerative marker in infectious diseases it could have in the 
setting of the acute septic myocardiopathy a meaning considerably different from the 
chronic lipid accumulation in CHF even though the microscopic aspect is similar. 
Certainly a lipidomic approach to the problem may be of great help. 
In conclusion notwithstanding similar morphological aspects and the involvement of many 
common biochemical pathways the cardiac dysfunction in sepsis and in CHF may have 
different meanings and consequences.  
9. Conclusions 
In the recent years the strict relationships between myocardial contractility and metabolism 
have been ascertained and a metabolic basis for cardiac contractile dysfunction verified in 
many clinical and experimental settings. Several metabolic alterations have been showed in 
CHF and septic myocardial dysfunction, their relationship with cardiac contractile 
dysfunction is not completely understood. They are probably a marker of the complex 
transcriptional and posttranscriptional alterations induced by the inflammatory, mechanical 
and metabolic stress the heart undergoes in both conditions and particularly of the 
coordinated compromise of mitochondrial function and of lipid oxidation but they represent 
also a direct inducer and amplifier of cellular damage. The significance of the morphological 
and metabolic alterations could be remarkably different in the slowly-evolving setting of 
CHF and in the acute one of the septic myocardial dysfunction, moreover the malignancy of 
the noxae underlying similar microscopic aspects may be very dissimilar. To understand in 
deep this aspect more thorough studies are needed. We currently do not know if they may 
represent a target for therapy because of the uncertain efficacy of the drugs until now used 
for this purpose but perhaps the light shed on the pathophysiological mechanism may give 
us an important help in the search for a future effective treatment.  
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